News | January 04, 2010

New Embolic Defector Used in First Clinical Experience

January 5, 2010 – St. Paul’s Hospital in Vancouver, Canada recently was the first to use the Embrella Embolic Deflector cerebral protection system. The device uses a porous membrane to deflect emboli away from the carotid arteries. It is inserted through the right radial or right brachial artery, away from the femoral artery, which is the typical access site for procedures. The device was used in a 91-year-old patient undergoing a balloon aortic valvuloplasty (BAV) procedure. During BAV procedures there is a risk that atheromatous plaque may be dislodged and travel to the brain during the passage of catheters around the aortic arch or during the subsequent balloon dilation of the stenotic and calcified aortic valve. The device was inserted through the right radial artery, and passed through the brachiocephalic artery and positioned along the greater curvature of the aorta. The device remained in position during the entire BAV procedure. “We were pleased to see how well the device tracked into the aorta and how easily it was positioned. It covered the orifice of the brachiocephalic, left common carotid and the left subclavian arteries,” said Dr. John Webb, director of cardiac catheterization and interventional cardiology, St. Paul’s Hospital. “There was no interaction with the device as we advanced several wires and catheters past the Embrella device enroute to the aortic valve.” The Embrella Embolic Deflector device is not available for clinical use in the United States. For more information:

Related Content

The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices| October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the
Claret Medical Closes $14.5 Million in Series C Financing for Sentinel Cerebral Protection System
News | Embolic Protection Devices| October 23, 2017
October 23, 2017 — Claret Medical announced that it has closed on a Series C financing of $14.5 million led by Lights
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices| April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices| March 22, 2017
March 22, 2017 — Two U.S.
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
InspireMD, CGuard, PARADIGM study, EuroPCR 2015, Musialek

Image courtesy of InspireMD

News | Embolic Protection Devices| June 23, 2015
InspireMD Inc. announced that its CGuard embolic prevention system reported positive results in the PARADIGM study at...
Overlay Init